Phase 2 study for people with Crohn's Disease and Colitis

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting

Phase Phase 2

Sponsor Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Registry number NCT06226883

Started 18 July 2024 Today 16 October 2026 Estimated completion 1 September 2028

Where this trial is running

Trial sites and the status recorded for each
Site	City	State or country	Status at this site
Southern Adelaide Local Health Network	Bedford Park	SA	Not yet recruiting
Royal Brisbane and Women's Hospital	Herston	QLD	Not yet recruiting
IBD SA SA Group of Specialists	Kurralta Park	SA	Not yet recruiting
The Alfred Hospital	Melbourne	VIC	Not yet recruiting
St. Vincent's Hospital	Melbourne	VIC	Not yet recruiting
Royal Perth Hospital	Perth	WA	Not yet recruiting
Sir Charles Gairdner Hospital	Perth	WA	Not yet recruiting
Princess Alexandra Hospital, Metro South Health	Woolloongabba, QLD	QLD	Not yet recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years to 85 Years

Sex Anyone, regardless of sex

Healthy volunteers Not accepted

Enrolment target 385

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

* Has signs/symptoms of CD for at least 90 days prior to screening

* Has a CDAI score of 220 to 450, with an average daily stool subscore ≥4 points and/or an average daily abdominal pain subscore of ≥2 points

* Has an SES-CD score of ≥6 (or an SES-CD score of ≥4 if CD is isolated to the ileum)

* Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: Corticosteroids, Immunosuppressants (eg, azathioprine, 6-mercaptopurine, methotrexate) and/or advanced therapies for CD (eg, biologic agents, Janus kinase \[JAK\] inhibitors, applicable investigational products)

Key Exclusion Criteria:

* Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or UC, or has clinical findings suggestive of UC

* Has CD that is isolated to the oral cavity, stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement

* Has had extensive bowel resection (\>100 cm), and/or more than 3 resections, and/or has a known diagnosis of short bowel syndrome

* Is currently receiving total parenteral nutrition, tube feeding, or a formula diet

* Has positive findings on a subjective neurological screening questionnaire

* Has a concurrent, clinically significant, serious, unstable comorbidity

* Previous treatment with vedolizumab or other licensed or investigational integrin inhibitors

* Is currently participating in any other interventional study or has received any investigational therapy within 30 days

* Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057

* Unable to attend study visits or comply with study procedures

* Has a history of any major neurological disorders, including: stroke, multiple sclerosis, brain tumor, demyelinating, or neurodegenerative disease

Dates on the record

Started 18 July 2024

Estimated completion 1 September 2028

Registry last updated 8 October 2026

Checked by Voxsanity 15 October 2026

Results, publications and the official record

No results are posted on the official record yet.
No publications are listed on the official record yet.
Official record and contacts on ClinicalTrials.gov – contact details for each site are kept there, and are not copied onto this page.

Sources and dates

ClinicalTrials.gov – the record this page reformats
ClinicalTrials.gov processing date: 8 October 2026.
This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.

Voxsanity

Clinical trials recruiting in Australia, from the public registries · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial, which may be relevant to my care:

Trial: NCT06226883

Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Phase: Phase 2

Status: Recruiting

Condition: Crohn's Disease and Colitis

More information: https://clinicaltrials.gov/study/NCT06226883

Eligibility criteria, as the registry published them

Reproduced exactly, unedited. Written for researchers rather than for patients.

Key Inclusion Criteria:

Has signs/symptoms of CD for at least 90 days prior to screening
Has a CDAI score of 220 to 450, with an average daily stool subscore ≥4 points and/or an average daily abdominal pain subscore of ≥2 points
Has an SES-CD score of ≥6 (or an SES-CD score of ≥4 if CD is isolated to the ileum)
Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: Corticosteroids, Immunosuppressants (eg, azathioprine, 6-mercaptopurine, methotrexate) and/or advanced therapies for CD (eg, biologic agents, Janus kinase [JAK] inhibitors, applicable investigational products)

Key Exclusion Criteria:

Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or UC, or has clinical findings suggestive of UC
Has CD that is isolated to the oral cavity, stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement
Has had extensive bowel resection (>100 cm), and/or more than 3 resections, and/or has a known diagnosis of short bowel syndrome
Is currently receiving total parenteral nutrition, tube feeding, or a formula diet
Has positive findings on a subjective neurological screening questionnaire
Has a concurrent, clinically significant, serious, unstable comorbidity
Previous treatment with vedolizumab or other licensed or investigational integrin inhibitors
Is currently participating in any other interventional study or has received any investigational therapy within 30 days
Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057
Unable to attend study visits or comply with study procedures
Has a history of any major neurological disorders, including: stroke, multiple sclerosis, brain tumor, demyelinating, or neurodegenerative disease

A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a registered health practitioner to access unapproved therapeutic goods for individual patients.

Not medical advice. Voxsanity reformats information published by public registries. It does not give medical advice and is not a substitute for talking to your doctor.